Transforming Health

Through Cutting-

Edge

Biopharma

Solutions

We are focused on advancing innovative therapies to address complex diseases and critical unmet medical needs, including ischemia and hypoxia in stroke, sickle cell disease, and cystic fibrosis.

discover our product

Prolong
Pharmaceuticals

Prolong Pharmaceuticals

Addressing critical
unmet medical needs.

We are a clinical-stage biopharmaceutical leader advancing innovative therapies across CNS, hematology, and respiratory disorders.

about us

Our Team

Innovative Leaders in Biotech

Our leadership team brings deep industry expertise and a strong global track record across pharmaceutical and biotechnology companies. Our founders pioneered PEGylation, a breakthrough drug delivery technology that has enabled transformative therapies for hepatitis, kidney disease, and other serious conditions, advancing innovation and expanding patient access worldwide.

meet the team

PP-007 Sanguinate®

Pipeline

PEGfinity™ Innovative Development

Our PEGylated candidates include a multifunctional gas transfer agent. The PEGfinity™ platform enables rapid lead generation and optimization of protein function and stability.

How it works

Multi-Modal Therapy

PP-007 (Sanguinate®) is designed to restore homeostasis by delivering oxygen to hypoxic tissues and carbon monoxide to support improved perfusion and reduced inflammation.

Clinical trials

Proven PEGylation Technology

PEGylation is a well-established technology used in FDA-approved therapies such as Neulasta® and Krystexxa®. We apply this technology in novel ways to address critical unmet medical needs.